報告題目🤽🏽‍♂️： Targeted Eradication of Malignant Cerebral Tumor

報告人：姜新義 教授

邀請人🕵🏻‍♂️：王飛虎 博士

報告時間： 3月 30日（周四） 14:00-15:40

地點：徐匯校區工程館100室

摘要：  

Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system, which is highly invasive. Surgical debulking is the first clinical intervention for GBM patient. However, GBM shows invasive growth, has no obvious boundary with normal brain tissue, and cannot be completely removed by surgery. The residual tumor cells after surgery still have strong proliferative capacity, are insensitive to radiotherapy and chemotherapy, and eventually lead to rapid recurrence of brain tumors within a few months. To explore an effective strategy of "specifically" eliminating invasive brain tumors is the key to prevent recurrence after GBM. Immunotherapy has brought unprecedented changes and hopes for cancer treatment. However, there is no successful immunotherapy program for GBM at present. Through the analysis of clinical samples of GBM patients, we confirmed that the expression levels of multiple biomarkers such as IDH1, IDO1 and CD133 in malignant brain tumor tissues were significantly increased, and were negatively correlated with the survival of patients. In view of this, we have constructed two nanocarrier-hydrogel superstructure drug delivery systems that can reshape the tumor immune microenvironment in situ to curb the recurrence of GBM after surgery: (i) induce immunogenic death, activate and recruit T lymphocytes, silence IDO1 to relieve the function and efficiency of Treg cell immune "brake", cascade to reshape the tumor killing immune microenvironment, and curb the recurrence of GBM after surgery; (ii) Generate CAR macrophages around the tumor cavity in vivo that can target the removal of glioma stem cells (GSCs), activate the adaptive immune system by its antigen presentation, remove residual GSCs after surgery, and avoid GBM tumor recurrence. Intracavity drug delivery offers a convenient and effective approach that can be seamlessly integrated with clinical surgical debulking without the need for additional surgery.

主講人簡介🏌🏼：姜新義，山東大學教授、藥劑學博士生導師，入選國家優秀青年人才項目，山東省高校“智能材料與藥物遞送”青創團隊帶頭人🕷，山東大學傑出中青年學者，山東大學“齊魯青年學者”，山東大學藥意昂4“智能材料與藥物精準遞送”團隊PI。

2013-2017年任Stanford University醫意昂4博士後研究員👨🏿‍🏭；2017年全職回國，先後承擔國家及省部級重點重大等課題10余項；已在Nature Nanotechnology👮🏽，Science Translational Medicine👟，Nature Communications🧑🏽‍🚒👨‍👧‍👦，PNAS，Science Advances，Advanced Materials🥻，ACS Nano等學術期刊上發表研論文50余篇；申報國家發明專利 20余項、PCT專利3項，10項已獲授權，9項已轉讓。應邀在國際控釋協會💕🕴🏻、中國藥學大會、生物醫學工程BMES等國內外學術會議上做口頭報告30余次，先後獲得國際先進材料協會科學家獎（2021）⛓，入選國際先進材料協會會士（2022），山東省醫學科技二等獎🏗🎿；指導研究生獲得全國藥學專業學位研究生優秀學位論文🖌，山東省研究生優秀成果一等獎等榮譽。目前擔任中國藥學會-藥劑專業委員會青年委員，中國顆粒學會-生物顆粒專業委員會委員，中國顆粒學會第三屆青年理事會理事，中國醫藥教育協會中藥製劑專業委員會常務委員, 山東省醫藥生物技術學會-細胞治療技術與標準化專業委員會委員；同時擔任Nature Nanotechnology🙆‍♀️，Science Translational Medicine🦸‍♀️，Nature Communications🧋🦦，PNAS🚝，Advanced Materials等30余個知名期刊特約審稿人🙆🏼。